CEACAM 6, a novel marker for the diagnosis of Barrett's esophagus

Research output: Contribution to journalArticle

Authors

  • Supriya Srivastava
  • Florian Kern
  • Wa Xian
  • Khay Guan Yeoh
  • Ming Teh
  • Frank McKeon
  • Khek Yu Ho

Colleges, School and Institutes

External organisations

  • Departments of Medicine and Pathology, National University Health System.
  • Departments of Cancer Science Institute, National University of Singapore.
  • Departments of Genome Institute of Singapore, A-STAR, Singapore.
  • Departments of Somatic Stem Cell Centre, University of Houston, USA.
  • Departments of Pathology, National University Health System.

Abstract

Barrett's esophagus (BE) is a premalignant condition associated with the development of esophageal adenocarcinoma (EAC). Despite the low risk of progression to EAC, evidence highlights the notably poor survival rates of this malignancy. The mainstay form of diagnosis of BE is endoscopy and biopsy sampling. However, research emphasizes limitations with regards to the histological detection of BE and associated dysplasia. The aim of this study is to evaluate the clinical significance of CEACAM6 as a potential biomarker for the diagnosis of BE and beyond. Retrospective tissue samples were obtained from columnar lined esophagus without goblet cells (n = 27), BE (n = 18), BE associated dysplasia (n = 16), and EAC (n = 24). Standardized immunohistochemistry for CEACAM6 was performed followed by quantitative staining analysis. Statistical analysis across the BE spectrum for CEACAM6 was undertaken and a P value <0.05 was considered significant. CEACAM6 expression increased from columnar lined epithelium (CLE) to BE with a subsequent decrease to dysplasia and adenocarcinoma. The expression of CEACAM6 was significant from CLE to BE at p 0.001, CLE to dysplasia at p 0.001, BE to dysplasia at p 0.006, CLE to adenocarcinoma at p 0.001 and BE to adenocarcinoma at p 0.001. There was no significant difference in expression between dysplasia and adenocarcinoma (P = 0.15). Our findings highlight the increasing expression of CEACAM6 from CLE to BE with a subsequent decrease to dysplasia and adenocarcinoma. In view of this, we advocate the utilization of this marker for the enhanced diagnosis of BE and for the distinction of BE and dysplasia.

Details

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalDiseases of the Esophagus
Volume30
Issue number7
Early online date19 Jul 2017
Publication statusPublished - Sep 2017

Keywords

  • Adenocarcinoma/metabolism, Aged, Antigens, CD/metabolism, Barrett Esophagus/diagnosis, Biomarkers/metabolism, Biopsy, Cell Adhesion Molecules/metabolism, Esophageal Neoplasms/metabolism, Esophagus/metabolism, Female, GPI-Linked Proteins/metabolism, Humans, Male, Middle Aged, ROC Curve, Retrospective Studies